Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Relay Therapeutics, Inc.NASDAQ: RLAY
Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares (diluted) growth accelerates
Q2 FY2026 weighted avg shares (diluted) of 202.85M shares rose 18.4% year over year, ahead of the +12.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 12.8% from the prior quarter. Over 3 fiscal years it compounded at +15.2% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.4% holds above the trailing-twelve-month pace of +12.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 171.59M USD
- Year-over-year change
- +20.1%
- 4-year CAGR
- +15.9%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 171.59M | +20.1% |
| FY2024 | 2024-12-31 | 142.87M | +16.6% |
| FY2023 | 2023-12-31 | 122.58M | +9.2% |
| FY2022 | 2022-12-31 | 112.23M | +18.0% |
| FY2021 | 2021-12-31 | 95.14M | — |
Weighted Avg Shares (Diluted) vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 weighted avg shares (diluted) of 181.67M shares is the 3rd highest of the 11 companies compared; the peer median is 92.22M shares.
- Its year-over-year change of +12.1% is the 6th highest of 11, against a peer median of +13.5%.
- Over three fiscal years its annual growth of +15.2% compares with a peer median of +19.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 310.86M | +9.7% | +32.5% | |
| LTM Jun 2026 | 197.09M | +10.9% | +33.1% | |
| LTM Jun 2026 | 181.67M | +12.1% | +15.2% | |
| LTM Sep 2026 | 145.89M | +32.5% | +9.8% | |
| LTM Aug 2026 | 108.1M | +31.0% | +21.3% | |
| LTM Mar 2026 | 92.59M | +31.1% | +30.3% | |
| LTM Jun 2026 | 91.85M | +16.0% | +16.1% | |
| LTM Mar 2026 | 88.86M | +4.6% | +28.8% | |
| LTM Mar 2026 | 74.4M | -1.9% | +17.6% | |
| LTM Mar 2026 | 60.14M | +2.0% | +12.5% | |
| LTM Mar 2026 | 40.11M | +19.2% | +4.7% | |
| Peer median (excluding RLAY) | 92.22M | +13.5% | +19.4% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M |
| Cost of Revenue | 169.39M | 243.01M | 326.39M | 315.44M | 3.56M |
| Gross Profit | (166.36M) | (241.62M) | (300.84M) | (305.43M) | 11.8M |
| Gross Margin | -5492.2% | -17496.3% | -1177.6% | -3052.2% | 76.8% |
| Research & Development | 295.65M | 246.36M | 330.02M | 319.09M | 261.38M |
| Selling, General & Admin | 59.75M | 69.33M | 78.58M | 80.24M | 56.71M |
| Operating Expenses | 198.34M | 57.65M | 72.16M | 67.03M | 314.54M |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| EBITDA | (223.08M) | (306.82M) | (374.15M) | (380.21M) | (272.92M) |
| EBITDA Margin | -7364.9% | -22217.4% | -1464.6% | -3799.4% | -1777.4% |
| Operating Income | (364.7M) | (299.28M) | (373M) | (372.47M) | (302.74M) |
| Operating Margin | -12040.2% | -21670.9% | -1460.1% | -3722.1% | -1971.6% |
| Interest Income | 830K | 8.79M | 31.05M | 34.75M | 27.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 826K | 8.77M | 31.03M | 34.76M | 26.26M |
| Income Before Tax | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Pre-Tax Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Net Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| EPS (Basic) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| EPS (Diluted) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| Weighted Avg Shares | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
| Weighted Avg Shares (Diluted) | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.